JLPC(SH:600513) Xin Lang Cai Jing·2025-09-04 09:11Core Viewpoint - The approval of the drug "Amlodipine Besylate Tablets" by the National Medical Products Administration is expected to enhance the product line and market competitiveness of the company and its subsidiary, but it is not anticipated to have a significant impact on recent operating performance [1] Group 1: Product Approval - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the drug registration certificate for Amlodipine Besylate Tablets, with specifications of 5mg and 10mg [1] - The total sales revenue for Amlodipine Besylate Tablets in hospitals nationwide for the year 2024 is projected to reach 1.216 billion yuan [1] Group 2: R&D Investment - Changle Pharmaceutical's research and development investment for this drug approval is approximately 3.83 million yuan [1]